compare the efficacy and safety of restore deb and sequent® please in chinese patient with coronary in-stent restenosis

Conditions: Coronary Restenosis

Summary: the purpose of this study is to evaluate the safety and efficacy of paclitaxel drug eluting balloons (restore deb, 3μg/mm2 balloon surface area ) for success of intervention treatment and maintaining the vessels unobstructed in the treatment of coronary in-stent restenosis compared with a product of the same category (sequent® please).


Eligibility criteria:
inclusion criteria: related to the patients: 1. age ≥18 years old 2. patients agree to receive follow-ups in month-1, 6, 9 and 12, and receive angiography in month-9. 3. patients are able to understand the objectives of the study mentally and in language. patients should indicate sufficient compliance to the study, and acknowledge all risks and benefits by signing the informed consent form. 4. patients with stable angina pectoris, or unstable angina pectoris, or old myocardial infarction, or proved asymptomatic regional myocardial ischemia 5. patients suitable to receive coronary revascularization of any type (including balloon angioplasty, stent implantation or coronary artery bypass grafting) related to the diseases: 6. restenosis mehran type i-iii after stent implantation (including bare metal stents, stents with inert coating, and stents with active coating) for the first time 7. diameter of the stent with restenosis should be 2.5-4.0mm (included). length of the stenosis lesion should be no more than 26mm, and diameter stenosis before operation should be ≥70%, or ≥50% with the evidence of ischemia. 8. one subject is allowed to have 2 target lesions at most, and 2 paclitaxel drug balloons for dilation. 9. the distance between lesions which require intervention and the target lesions must be \>10mm. exclusion criteria: related to the patients: 1. pregnant or lactating women, or women who plan to get pregnant within 12 months or refuse to take effective contraceptives. 2. the patients are participating in any other clinical trials before reaching the primary endpoints. 3. the patients have a life expectancy of less than 12 months, or it would be difficult to finish follow-ups within 12 months. 4. the patients had cerebral stroke within 6 months before being included, or have a history of peptic ulcer or gastrointestinal bleeding in the past 6 months, or the patients have a bleeding tendency according to the investigator. 5. patients with a history of leukopenia (white blood cell count \<3×109/l for more than 3 days) or neutropenia (anc\<1000/mm3 for more than 3 days) or thrombocytopenia (platelet \<100,000/mm3) 6. patients who are forbidden to use anticoagulation agents or anti-platelet drugs, and unable to tolerate aspirin or clopidogrel 7. patients with renal insufficiency (egfr\<30ml/min) 8. patients who are known to be allergic to paclitaxel 9. patients who had myocardial infarction within 1 week before being included 10. patients who had heart transplantation 11. patients with severe congestive heart failure or nyha grade iv heart failure 12. patients with severe valvular heart disease 13. patients who are unsuitable for the study according to the investigator due to other reasons related to the diseases: 14. patients with evidence of extensive thrombosis in the target vessel before intervention 15. patients with total occlusion indicating timi 0 blood flow at the target lesion (mehran type iv stenosis) 16. patients with multiple lesions (≥3) requiring percutaneous coronary intervention treatment in the same artery 17. patients with lesions requiring intervention treatment in 3 vessels 18. the diameter of the branch lesions in the target lesion ≥2.5mm 19. patients already treated with cabg after in-stent restenosis 20. lm lesions and ostial lesion within 5mm to the root aorta